

OPEN ACCESS

EDITED AND REVIEWED BY Christophe Lacroix, ETH Zürich, Switzerland

*CORRESPONDENCE
Bowen Li

☑ lbw1965841356@qmail.com

RECEIVED 27 August 2025 ACCEPTED 08 September 2025 PUBLISHED 23 September 2025

CITATION

Li B, Bottacini F and Yang Y (2025) Editorial: Dietary modulation of gut microbiota-X axis. Front. Nutr. 12:1693629. doi: 10.3389/fnut.2025.1693629

COPYRIGHT

© 2025 Li, Bottacini and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: Dietary modulation of gut microbiota-X axis

Bowen Li^{1*}, Francesca Bottacini² and Yuhui Yang³

¹College of Food Science, Southwest University, Chongqing, China, ²Department of Biological Sciences, Munster Technological University, Cork, Ireland, ³College of Food Science and Engineering, Henan University of Technology, Zhengzhou, China

KEYWORDS

gut microbiota-X axis, gut, dietary, microbiota, health

Editorial on the Research Topic

Dietary modulation of gut microbiota-X axis

1 The gut microbiota-X axis: an integrative physiological framework

The concept of the "Gut Microbiota-X axis" signifies a fundamental shift in our understanding of how diet systemically influences host physiology via microbial mediation (1). This axis embodies a dynamic, multidirectional communication network in which gut commensals metabolize nutritional substrates into bioactive compounds—such as vitamins, neurotransmitters, and immunomodulators—that directly engage with extra-intestinal organs (2). Accumulating evidence establishes gut microbiota as key metabolic interpreters, translating dietary intake into molecular signals that modulate the neuro-endocrine-immune network (3).

Central to this paradigm is the role of the gut microbiota—a diverse ecosystem of bacteria, archaea, viruses, and fungi—which acts as a metabolic interface, converting dietary and host-derived compounds into bioactive molecules. Notable among these are microbiota metabolites like short-chain fatty acids (SCFAs; e.g., butyrate, propionate, and acetate), produced from dietary fiber fermentation, which function as epigenetic regulators through histone deacetylase (HDAC) inhibition (4). Similarly, microbial transformation of primary bile acids into secondary bile acids activates nuclear receptors such as FXR and TGR5, thereby modulating metabolic and inflammatory pathways systemically (5).

The immune system serves as a major conduit for this cross-organ communication. Microbial components and metabolites continuously interact with gut-associated lymphoid tissue (GALT), shaping immune cell differentiation (e.g., of regulatory T cells) and cytokine production, which in turn exert distal effects on organ inflammation and functionality (6). Additionally, the vagus nerve provides a direct neural pathway through which gut signals influence central nervous system activity, while endocrine mechanisms involving gut hormones such as peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) further integrate metabolic and cognitive functions (7). Dysbiosis—a disruption of microbial homeostasis—compromises this intricate exchange, often increasing intestinal permeability and permitting leakage of microbial products like lipopolysaccharide (LPS) into circulation (8). This can initiate a state of chronic low-grade inflammation, contributing to the pathophysiology of multiple diseases across organ systems, including Alzheimer's disease (via the gut-brain axis) (9), non-alcoholic fatty liver disease (via the gut-liver axis) (10), and psoriasis (via the

Li et al. 10.3389/fnut.2025.1693629

gut-skin axis) (11). Thus, the gut microbiota-X axis functions as a critical physiological integrator, wherein diet-microbiota interactions fine-tune systemic homeostasis and organismal resilience.

2 Thematic advancements: mechanistic elucidation and clinical translation

This Research Topic compiles cutting-edge research exploring the intricate bidirectional relationship between dietary components and the gut microbiota-X axis, emphasizing its profound implications for host health and disease pathogenesis. The collected studies employ diverse methodologies-ranging from preclinical animal models and randomized controlled trials (RCTs) to large-scale epidemiological analyses and systematic reviews to elucidate specific mechanisms and therapeutic potentials. A prominent theme is the targeted use of probiotics to modulate gut microbial composition and function for health benefits. Key findings demonstrate the efficacy of specific strains, such as Bifidobacterium adolescentis CCFM1447 in mitigating osteoporosis by enriching intestinal bacteria capable of vitamin D conversion (Yu, Tian et al.), and Bifidobacterium longum subsp. infantis CCFM1426 enhances the anti-colitic effects of vitamin A through retinoic acid restoration and microbiota modulation in murine models of ulcerative colitis (Yu, Huang et al.). The translational potential of probiotics is further supported by an RCT showing specific formulations (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus; 3×10^9 CFU) effectively mitigate stress and inflammation in malnourished adults via gut microbiota modulation (Ahmadi-Khorram et al.). Beyond live bacteria, the issue explores broader dietary strategies, including granola with multiple prebiotics increasing Bifidobacterium abundance and improving stress/sleepiness in Japanese participants (Sasaki et al.), and the therapeutic application of fecal microbiota transplantation (FMT) in severe food intolerance (Huang, Huang et al.).

A second major focus involves the development and application of novel indices to quantify the relationship between diet, gut microbiota, and disease risk in human populations. Several studies leverage the US National Health and Nutrition Examination Survey (NHANES) data to establish significant associations between a proposed "dietary index for gut microbiota" and specific pathologies. Zhang X. et al. link this index to female infertility, while Wang et al. demonstrate its correlation with metabolic dysfunction-associated steatotic liver disease (MASLD). Most notably, Huang, Liu et al. establish an association between this dietary index and diabetes, proposing phenotypic age and body mass index (BMI) as significant mediators in this relationship, highlighting the complex interplay of diet, microbes, metabolic health, and aging. The critical role of microbial metabolites beyond vitamins is underscored in a systematic review and meta-analysis by Xie L. et al., which synthesizes preclinical evidence supporting the therapeutic potential of microbially-derived short-chain fatty acids (SCFAs) for acute lung injury. Furthermore, a review by Zhang R. et al. examines the intricate links between dietary habits, the gut-brain axis, and cognitive function, emphasizing the microbiota's role in neurobehavioral outcomes. Supporting this, Ding et al. present evidence suggesting early childhood probiotic intake may modify the association between prenatal micronutrient supplementation and neurobehavioral development in preschoolers. Finally, Xie Q. et al. review the emerging therapeutic potential of probiotics and postbiotics in targeting apoptosis for the treatment and prevention of digestive diseases. Collectively, this Research Topic significantly advances our understanding of how dietary components-from specific foods and supplements to broader dietary patterns-can be strategically manipulated to shape gut microbial communities and their functional outputs (vitamin conversion, SCFA production, immune modulation, neuroactive metabolite generation), thereby offering novel avenues for preventing and treating a wide spectrum of conditions including metabolic diseases, gastrointestinal disorders, osteoporosis, neurological impairments, and inflammatory states. The research highlights the move toward personalized nutrition and microbiotatargeted therapeutics while also identifying key areas for future investigation, such as refining dietary indices, elucidating strainspecific effects, and translating preclinical findings into robust clinical applications.

3 Future insights

Future research on the dietary modulation of the gut microbiota-X axis will likely focus on precision nutrition strategies that account for individual variability in microbiome composition, host genetics, and environmental factors. A key direction involves the development of targeted interventions using specific dietary components-such as prebiotics, polyphenols, and fermented foods-to selectively modulate microbial taxa and metabolic pathways that influence the X axis (e.g., brain, liver, or bone). Advanced multi-omics integration, including metagenomics, metabolomics, and transcriptomics, will be essential to elucidate mechanistic links between diet, microbial metabolites (e.g., SCFAs, bile acids, and tryptophan derivatives), and host physiological outcomes. Furthermore, long-term randomized controlled trials and longitudinal studies are needed to establish causal relationships and evaluate the sustainability of dietary interventions in improving health outcomes related to the microbiota-X axis.

Another promising area is the application of artificial intelligence and machine learning to analyze complex datasets and predict individual responses to dietary interventions. This approach could enable the design of personalized dietary recommendations that dynamically adapt to shifts in an individual's gut microbiome and health status. Additionally, there is growing interest in exploring the role of chrono nutrition and meal timing in modulating microbial rhythms and their interactions with host circadian biology. Future studies should also investigate the synergistic effects of diet and other lifestyle factors, such as exercise and stress management, on the microbiota-X axis. Ultimately, translating these insights into clinical practice and public health nutrition will require interdisciplinary collaboration and the development of functional foods or nutraceuticals that are evidence-based, effective, and accessible.

Li et al. 10.3389/fnut.2025.1693629

Author contributions

BL: Funding acquisition, Investigation, Project administration, Visualization, Writing – original draft. FB: Project administration, Validation, Visualization, Writing – review & editing. YY: Project administration, Resources, Validation, Visualization, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the earmarked funds from the Fundamental Research Funds for the Central Universities (SWU-KQ25008).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Generative AI statement

The author(s) declare that no Gen AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- 1. Lin X, Yu Z, Liu Y, Li C, Hu H, Hu J-C, et al. Gut-X axis. *iMeta*. (2025) 4:e270. doi: 10.1002/imt2.270
- 2. Li F, Peng X, Li W. The interaction between various food components and intestinal microbiota improves human health through the gut–X axis: independently or synergistically. Food Funct. (2025) 16:2172–93. doi: 10.1039/D4FO04430D
- 3. Luo T, Che Q, Guo Z, Song T, Zhao J, Xu D. Modulatory effects of traditional Chinese medicines on gut microbiota and the microbiota-gut-x axis. *Front Pharmacol.* (2024) 15:1442854. doi: 10.3389/fphar.2024.1442854
- 4. Fawad JA, Luzader DH, Hanson GF, Moutinho TJ, McKinney CA, Mitchell PG, et al. Histone deacetylase inhibition by gut microbe-generated short-chain fatty acids entrains intestinal epithelial circadian rhythms. *Gastroenterology.* (2022) 163:1377–90.e11. doi: 10.1053/j.gastro.2022.07.051
- 5. Yan M, Man S, Sun B, Ma L, Guo L, Huang L, et al. Gut liver brain axis in diseases: the implications for therapeutic interventions. *Signal Transduct Target Ther.* (2023) 8:443. doi: 10.1038/s41392-023-01673-4
- 6. Jan P, Nikola M, Liliana T, Karolina K, Valéria G, Zdeněk Z, et al. Microbiota modulate immune cell populations and drive dynamic

- structural changes in gut-associated lymphoid tissue. Gut Microbes. (2025) 17:2543908. doi: 10.1080/19490976.2025.2543908
- 7. Khan MT, Zohair M, Khan A, Kashif A, Mumtaz S, Muskan F. From gut to brain: the roles of intestinal microbiota, immune system, and hormones in intestinal physiology and gut-brain-axis. *Mol Cell Endocrinol.* (2025) 607:112599. doi: 10.1016/j.mce.2025.112599
- 8. Stevens BR, Goel R, Seungbum K, Richards EM, Holbert RC, Pepine CJ, et al. Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression. *Gut.* (2018) 67:1555. doi: 10.1136/gutjnl-2017-314759
- 9. Ohara TE, Hsiao EY. Microbiota–neuroepithelial signalling across the gut–brain axis. *Nat Rev Microbiol.* (2025) 23:371–84. doi: 10.1038/s41579-024-01136-9
- 10. Hsu CL, Schnabl B. The gut–liver axis and gut microbiota in health and liver disease. *Nat Rev Microbiol.* (2023) 21:719–33. doi: 10.1038/s41579-023-00904-3
- 11. Millman JF, Kondrashina A, Walsh C, Busca K, Karawugodage A, Park J, et al. Biotics as novel therapeutics in targeting signs of skin ageing via the gut-skin axis. *Ageing Res Rev.* (2024) 102:102518. doi: 10.1016/j.arr.2024.102518